Image

Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds

Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

ORBITA-SOLAR is an invasive physiological cardiac catheterisation study that aims to determine whether different coronary stenoses have different angina thresholds. The angina threshold is defined as the amount of coronary flow reduction required to reproduce symptoms. Sixty patients with symptoms of stable angina and 2 coronary artery stenoses amenable to percutaneous coronary intervention (PCI) will be recruited. This study will use intra-coronary balloon inflation during supine exercise on an ergometer to measure the fractional flow reserve (FFR) and non-hyperemic pressure ratio (NHPR) that relates to angina onset, in real time, at the location of each stenosis.

Eligibility

Inclusion Criteria:

  1. Eligibility for PCI due to angina or angina-equivalent symptoms on exertion
  2. 2 severe epicardial stenoses in a major coronary artery, defined as:
    1. ≥70% stenosis in a coronary artery with ≥2.5mm diameter, on invasive coronary angiography (ICA)
    2. Severe stenosis in a vessel with ≥2.5mm diameter, on CTCA
  3. Evidence of ischaemia on an invasive or non-invasive test, including:
    1. Physiological test during invasive coronary angiography (ICA)
    2. Dobutamine stress echocardiography (DSE)
    3. Stress perfusion cardiac magnetic resonance (CMR)
    4. Myocardial perfusion scintigraphy (MPS)
    5. Fractional flow reserve computed-tomography (FFR-CT)

Exclusion Criteria:

  1. Age \<18 years
  2. Acute coronary syndrome within 3 months
  3. Previous coronary artery bypass graft
  4. Significant left main stem disease
  5. Single lesion amenable to PCI
  6. Chronic total occlusion of the target artery
  7. Moderate to severe valve disease
  8. LVEF ≤40%, contraindication to PCI or drug-eluting stents
  9. PCI performed with drug-eluting balloons without stenting
  10. Contraindication to antiplatelet therapy
  11. Contraindication to adenosine
  12. Physical inability to exercise with an ergometer
  13. Femoral artery access
  14. Pregnancy
  15. Inability to consent

Study details
    Angina (Stable)
    Ischaemic Heart Desease
    Coronary Artery Disease(CAD)

NCT07386418

Imperial College London

26 February 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.